- Home
- ALIT vs DNLI Comparison
ALIT vs DNLI Comparison
Compare ALIT & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALIT
- DNLI
- Stock Information
- Founded
- ALIT 2017
- DNLI 2013
- Country
- ALIT United States
- DNLI United States
- Employees
- ALIT N/A
- DNLI N/A
- Industry
- ALIT Business Services
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALIT Consumer Discretionary
- DNLI Health Care
- Exchange
- ALIT Nasdaq
- DNLI Nasdaq
- Market Cap
- ALIT 2.0B
- DNLI 2.1B
- IPO Year
- ALIT N/A
- DNLI 2017
- Fundamental
- Price
- ALIT $3.61
- DNLI $13.47
- Analyst Decision
- ALIT Strong Buy
- DNLI Strong Buy
- Analyst Count
- ALIT 6
- DNLI 16
- Target Price
- ALIT $8.75
- DNLI $33.62
- AVG Volume (30 Days)
- ALIT 7.7M
- DNLI 2.0M
- Earning Date
- ALIT 11-11-2025
- DNLI 11-05-2025
- Dividend Yield
- ALIT 4.35%
- DNLI N/A
- EPS Growth
- ALIT N/A
- DNLI N/A
- EPS
- ALIT N/A
- DNLI N/A
- Revenue
- ALIT $2,311,000,000.00
- DNLI N/A
- Revenue This Year
- ALIT $0.73
- DNLI N/A
- Revenue Next Year
- ALIT $3.11
- DNLI $802.87
- P/E Ratio
- ALIT N/A
- DNLI N/A
- Revenue Growth
- ALIT N/A
- DNLI N/A
- 52 Week Low
- ALIT $3.55
- DNLI $10.57
- 52 Week High
- ALIT $8.93
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- ALIT 33.29
- DNLI 35.90
- Support Level
- ALIT $3.55
- DNLI $14.63
- Resistance Level
- ALIT $3.78
- DNLI $15.69
- Average True Range (ATR)
- ALIT 0.15
- DNLI 0.72
- MACD
- ALIT 0.03
- DNLI -0.21
- Stochastic Oscillator
- ALIT 9.24
- DNLI 2.04
About ALIT Alight Inc.
Alight Inc is a technology-enabled services company delivering human capital management solutions to many of complex organizations. This includes the implementation and administration of employee benefits (e.g., health, wealth and leaves benefits) solutions, currently operates under one reportable segment, Employer Solutions. The Company completed the Divestiture of Alight's Professional Services segment and Alight's Payroll & HCM Outsourcing business within the Employer Solutions segment. The company operates in USA states and International market too.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.